Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals
Executive Summary
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.